Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 27,880 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke.DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER, BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Changing stroke rehab and research worldwide now.Time is Brain!trillions and trillions of neuronsthatDIEeach day because there areNOeffective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.
What this blog is for:
My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.
Tuesday, February 4, 2020
Abbott to test its heart device against lifetime blood thinners for reducing stroke risk
For those of you with atrial fibrillation, discuss with your doctor.
Abbott plans to launch a
head-to-head study that puts its structural heart device up against a
newer generation of blood thinners, testing its ability to lower the
risk of strokes in people with atrial fibrillation.
The devicemaker’s Amplatzer Amulet occluder is designed to
permanently block a small, naturally forming pouch that develops within
the muscle wall of the heart’s left atrium. In people with an irregular
pulse, this appendage can fail to drain completely with each heartbeat;
the blood that pools there can form clots that, once loose and pumped
out of the heart, can cause debilitating or fatal strokes.
The randomized study, dubbed CATALYST,
will evaluate the device’s performance over at least two years compared
to blood thinners known as non-vitamin K antagonist oral
anticoagulants, or NOACs, and as an alternative to the lifetime regimens
that currently serve as a standard-of-care for patients with AFib.
FREE DAILY NEWSLETTER
Like this story? Subscribe to FierceBiotech!
Biopharma is a fast-growing world where big ideas come
along every day. Our subscribers rely on FierceBiotech as their
must-read source for the latest news, analysis and data in the world of
biotech and pharma R&D. Sign up today to get biotech news and
updates delivered to your inbox and read on the go.
This class of drugs includes blockbusters like
Eliquis, Xarelto and Pradaxa, which are now recommended over warfarin
in cardiology treatment guidelines.
"A device that can address a significant structural issue of the
heart via a minimally invasive procedure would be a significant step
forward for patients with atrial fibrillation eligible for long-term
NOAC therapy," said the study’s principal investigator, Vivek Reddy,
director of Cardiac Arrhythmia Services for The Mount Sinai Hospital. RELATED: Abbott names new CFO shortly ahead of CEO transition
The Amplatzer Amulet occluder. (Abbott)
Starting next month, the study plans to enroll up to 2,650
participants at 150 global sites, measuring rates of ischemic strokes,
embolisms or cardiovascular mortality, as well as major bleeding events.
Delivered to the heart by a catheter, the Amplatzer Amulet previously
received a CE mark in 2013.
"The CATALYST trial has the potential to provide data for the
Amplatzer Amulet LAA Occluder that could change clinical practice by
eliminating a lifetime need for blood thinners—reinforcing our mission
of helping people live better lives through better health,” Neil Moat,
chief medical officer of Abbott’s structural heart business, said in a statement.
Abbott estimates that the prevalence of atrial fibrillation will rise
over the coming decade to at least 12.1 million cases, with strokes
related to AFib being nearly twice as fatal compared to unrelated
strokes.
No comments:
Post a Comment